id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zXzu1K7LEemJrleIsbLt5A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gas6,ion and aggregationOrally active, (growth arrest-specific gene 6),TextQuoteSelector,TextPositionSelector,26774,26778,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:03:15.821199+00:00
z42Byq7GEemNrfud7uDdYA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,atheroma, properties. At the site of the ," rupture, platelet-released T×A2",TextQuoteSelector,TextPositionSelector,12776,12784,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:27:31.646425+00:00
yhH2hK7DEemo2t-USsJAxA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y1 receptor,on to occur. Signaling from the , causes platelet shape change an,TextQuoteSelector,TextPositionSelector,11644,11657,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:05:53.771242+00:00
yQW8_q7CEem_1IfJNxVbgQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,αIIbβ3 integrin receptor,cretion; P-selectin expression; ,; platelet activationPAR-1 and P,TextQuoteSelector,TextPositionSelector,10984,11008,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:58:42.651877+00:00
yNLPsK7HEemx13vaPZk2sA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,phospholipase C,"r, which leads to shape change, "," (PLC) activation, thromboxane A",TextQuoteSelector,TextPositionSelector,14752,14767,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:34:30.068391+00:00
y5PD-K7MEemrXktBPdiU6g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PI3K,oteinases (MMPs)By potentiating ," activation, MMP-2 amplifies pla",TextQuoteSelector,TextPositionSelector,27336,27340,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:10:22.145637+00:00
xWiZBK9sEem9UVfxnmMWHw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,trans-membrane protein,D40 ligand (CD40L; CD 154) is a , expressed on the surface of act,TextQuoteSelector,TextPositionSelector,52791,52813,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:15:31.022727+00:00
vsXmJK7HEemLgi8qIPTBng,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PAR-1 receptor,ular targets. Thrombin binds to ,", which leads to shape change, p",TextQuoteSelector,TextPositionSelector,14707,14721,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:34:13.060544+00:00
veGrGK7BEem-08v2NdsJkw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gai-coupled P2Y12,(s)CommentsADPGaq-coupled P2Y1; ,P2Y1: shape change; P2Y12: aggre,TextQuoteSelector,TextPositionSelector,10575,10592,"WT_DS,GP",no,[WT_DS][GP],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:51:14.597955+00:00
vEjlnK9qEem_j6tiGtDcqw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,"erious vascular events (stroke, ",", or vascular death) were second",TextQuoteSelector,TextPositionSelector,44837,44860,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:00:56.970251+00:00
v1yZ3q7MEemkU1MkQWbEKQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,MMPs,ranesMatrix metalloproteinases (,)By potentiating PI3K activation,TextQuoteSelector,TextPositionSelector,27315,27319,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:10:01.566685+00:00
uABGyLRcEemgb9OH-aCp_A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12 platelet receptor,pidogrel irreversibly binds the , after a two-step activation by ,TextQuoteSelector,TextPositionSelector,17871,17894,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T13:03:12.600657+00:00
u6bd1q7CEemdOVvvy-Zizw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P-selectin,change; ADP and T×A2 secretion; , expression; αIIbβ3 integrin rec,TextQuoteSelector,TextPositionSelector,10961,10971,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:58:20.223573+00:00
twZC9K7LEemJHsex1rElfw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,collagen,orsOrally activeDZ-697bInhibits , and ristocetin-mediated platele,TextQuoteSelector,TextPositionSelector,26695,26703,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:02:38.168180+00:00
tg4IfK7MEem4hyeoekmi2w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Matrix metalloproteinases,tidylserine-containing membranes, (MMPs)By potentiating PI3K acti,TextQuoteSelector,TextPositionSelector,27288,27313,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:09:45.917282+00:00
stAdVq7JEemfbCtijuDO5g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CAD,s with coronary artery disease (,) and PCI. Several methods were ,TextQuoteSelector,TextPositionSelector,19509,19512,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:48:12.001687+00:00
sjjLOq9qEemLxAPKGzT0sQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,stroke,ers of serious vascular events (,", acute coronary syndrome, or va",TextQuoteSelector,TextPositionSelector,44829,44835,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:00:39.952886+00:00
s4qB-q4aEem7IAeVzhw5IQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,vis,"t all, these limitations. Vis-à-"," their net clinical benefit, the",TextQuoteSelector,TextPositionSelector,8868,8871,WT_GP,yes,[WT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:55:31.253703+00:00
rzD3Sq9rEembf9OPIijCQA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,intermittent claudication,ible for inclusion if they have , in conjunction with an ankle-br,TextQuoteSelector,TextPositionSelector,50450,50475,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:07:44.285917+00:00
ry86Cq4bEem4lPNTTyl-MQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,fibrin,"idges, which, once converted to ",", ultimately contribute to throm",TextQuoteSelector,TextPositionSelector,10240,10246,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:02:33.375668+00:00
rs9mLNCNEemV8sst4T2A6Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12 receptors,ined inhibition of thrombin and , leads to a synergistic inhibito,TextQuoteSelector,TextPositionSelector,13992,14007,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:04:15.035636+00:00
rccRmK7nEemKVfe40W1xAw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,unstable angina, found both among patients with , and non-STEMI and STEMI subject,TextQuoteSelector,TextPositionSelector,32229,32244,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:22:48.423599+00:00
qfMA7q7KEemrVFcNDzszrQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,VASP,ator-stimulated phosphoprotein (,)-tailored clopidogrel loading d,TextQuoteSelector,TextPositionSelector,23307,23311,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:55:06.742576+00:00
q8KH4q7JEemSP0OaWQHWZA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,coronary artery disease,"outcome in ≈4,500 patients with ", (CAD) and PCI. Several methods ,TextQuoteSelector,TextPositionSelector,19484,19507,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:48:00.092804+00:00
pR5iqq7CEemNnTOwqiLg3w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,COX-1,"ggregationIn endothelial cells, ",-derived PGH2 is converted into ,TextQuoteSelector,TextPositionSelector,10794,10799,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:57:42.554209+00:00
pOzKfK4aEemP8XckokhXTA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,stroke,"al infarction (−32%), non-fatal "," (−25%), and of cardiovascular d",TextQuoteSelector,TextPositionSelector,8707,8713,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:55:06.756792+00:00
pN3a-q9sEemOQaPfdyNDxA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ADP-receptor,y of agonists in an aspirin- or , antagonist-independent fashion ,TextQuoteSelector,TextPositionSelector,52495,52507,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:14:36.591156+00:00
oyTSkK7MEemkUXcJ8j-zTQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent Gla,"Tyro3, Axl, MerTK); through its ", module it interacts with phosph,TextQuoteSelector,TextPositionSelector,27200,27223,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:09:14.198937+00:00
oUD6DK7DEemNUu-gY4Yb5g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαi, activation of both the Gαq and , pathways by ADP is needed for p,TextQuoteSelector,TextPositionSelector,11560,11563,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:04:45.633702+00:00
oNnvEK7IEemIG6_u0xTp_g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,GpIIb,"el, cangrelor, ticagrelor), and ",/ Ilia receptor antagonists (abc,TextQuoteSelector,TextPositionSelector,15963,15968,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:40:32.283437+00:00
oKwFvK9qEemMOyP1GSRwoQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,cerebral infarction,"64), 1,510 patients with recent ", were randomly assigned to recei,TextQuoteSelector,TextPositionSelector,44571,44590,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:00:10.529104+00:00
mshcjK9pEemgJxMTfoJh4Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,bleeding tendency,ed with a worse safety (greater ,).A concerted effort that takes ,TextQuoteSelector,TextPositionSelector,55235,55252,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:52:51.174704+00:00
mjYkbNCNEemSbLtZvxtqpg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ischemia,"I, silent AMI, severe recurrent ",", stroke, and death. However, th",TextQuoteSelector,TextPositionSelector,39266,39274,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:03:40.343968+00:00
luHwoK4bEemXlxN08lxCcA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,fibrinogen,ation and spreading by means of ," bridges, which, once converted ",TextQuoteSelector,TextPositionSelector,10195,10205,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:01:52.264340+00:00
lV7OoK9rEembfh-aOy8IZQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,peripheral artery disease,ime of inclusion. Patients with , (PAD) are eligible for inclusio,TextQuoteSelector,TextPositionSelector,50378,50403,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:07:01.064392+00:00
l1LjsK4aEemjgi8W-4PyQQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,myocardial infarction,nificant reduction of non-fatal ," (−32%), non-fatal stroke (−25%)",TextQuoteSelector,TextPositionSelector,8667,8688,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:54:44.008275+00:00
l0IfoK9sEemZnyuCBB4qXw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,phosphoinositide-3 kinase,"77). Active MMP-2, potentiating "," activation, amplifies platelet ",TextQuoteSelector,TextPositionSelector,52375,52400,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:14:13.843131+00:00
jvTS1q7oEemSd3MRRrVzUw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,diabetes,it being found in patients with ,", with coronary stents, or with ",TextQuoteSelector,TextPositionSelector,34814,34822,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:29:05.892586+00:00
jtcl9q4bEemzEs_GMVxYyQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,αIIbβ3 integrin,"on, glycoprotein (Gp) IIb/IIIa (",) mediates platelet aggregation ,TextQuoteSelector,TextPositionSelector,10122,10137,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:01:39.279946+00:00
jUkaIK9tEem_utvo501bQg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Transmembrane protein,and blunting platelet reactivity, expressed on the surface of act,TextQuoteSelector,TextPositionSelector,27805,27826,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:21:06.496469+00:00
jFRFwK7KEemJbttB4VhqGA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,vasodilator-stimulated phosphoprotein,4.2% of patients (36).Whereas a , (VASP)-tailored clopidogrel loa,TextQuoteSelector,TextPositionSelector,23268,23305,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:54:16.693470+00:00
j1IOBK7HEemSe-dRfQWOTg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12 receptors,ined inhibition of thrombin and , leads to a synergistic inhibito,TextQuoteSelector,TextPositionSelector,13991,14006,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:32:53.468322+00:00
iEAYpK7CEemjDyNkgdBsbQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,5HT-2A receptors, Gai-coupled receptors)Serotonin,Shape change; platelet recruitme,TextQuoteSelector,TextPositionSelector,11104,11120,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:56:54.102755+00:00
i8RASK4aEemnv_NZT2AZJA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ischemic stroke,"s (acute myocardial infarction, ","). In view of this, platelets ar",TextQuoteSelector,TextPositionSelector,8321,8336,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:54:24.159810+00:00
herZ7K9qEemOMIfcLHrbHA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,5-HT platelet receptors,ate is a selective inhibitor of ,". In the S-ACCESS trial (64), 1,",TextQuoteSelector,TextPositionSelector,44491,44514,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:59:25.647662+00:00
guKCWLRcEembzLOCikdUgg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ischemia-reperfusion injury,ve effects in hearts exposed to , (79). MMP-2 gene-silencing tech,TextQuoteSelector,TextPositionSelector,52626,52653,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T13:01:43.418745+00:00
gd1POq7IEemyNMuf5HKNEQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Ac, associated with adenylcyclase (,) down-regulation and decreased ,TextQuoteSelector,TextPositionSelector,15587,15589,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:39:40.483643+00:00
gT3s2K9tEemmNB9VWnbX6w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CD40,). Therapeutic targeting of the ,-CD40L axis using humanized anti,TextQuoteSelector,TextPositionSelector,53068,53072,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:20:46.383184+00:00
fjiQ1K7HEemyMV_C8ifPzg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gβi,. By blocking Gαq via PAR-1 and ," via P2Y12, combined inhibition ",TextQuoteSelector,TextPositionSelector,13940,13943,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:32:24.884820+00:00
fhYO6K7LEemLcP983PL3GQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,interleukin 6,nflammatory markers (sCD40L and , and the expression of P-selecti,TextQuoteSelector,TextPositionSelector,26532,26545,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:01:01.879621+00:00
f2m0Yq4bEemXlWtHDXT6gQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,glycoprotein (Gp) IIb,"atelets (2,3). Upon activation, ",/IIIa (αIIbβ3 integrin) mediates,TextQuoteSelector,TextPositionSelector,10094,10115,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:01:13.354182+00:00
dfRdBK9sEemBdMta8XKHgw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gas6 receptors,ing the extracellular domain of ,", or by inactivation of RNA for ",TextQuoteSelector,TextPositionSelector,51918,51932,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:13:17.942436+00:00
deT-Jq7DEemxw_-Upapy_A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptor,q-coupled receptor P2Y1 and the , P2Y12. The concomitant activati,TextQuoteSelector,TextPositionSelector,11485,11505,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:03:32.924329+00:00
d-Kg_rRcEemq1QNbfcC6Tg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,injury,latelet recruitment at sites of , (3). It may also play a pro-coa,TextQuoteSelector,TextPositionSelector,14268,14274,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T13:01:24.913597+00:00
brGprq7KEemJGSt5DxwcvA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,diabetic angiopathy,culation has been documented in , or in patients with coronary ar,TextQuoteSelector,TextPositionSelector,22140,22159,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:53:27.341489+00:00
bhVQLq7DEemKEG-WZsJ7QQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαq-coupled receptor,"o the P2 purinergic family, the ", P2Y1 and the Gαi-coupled recept,TextQuoteSelector,TextPositionSelector,11451,11471,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:03:19.819211+00:00
bcAACK9rEemmJ3tFtXaVoA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,atherosclerotic disease,nt of patients with established , receiving standard therapy (up ,TextQuoteSelector,TextPositionSelector,50159,50182,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:05:54.560521+00:00
b3VWQK7HEemo6BfcD1SQdA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαi-linked ADP receptor," by secreted ADP, acting on the ",. By blocking Gαq via PAR-1 and ,TextQuoteSelector,TextPositionSelector,13885,13908,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:32:00.131165+00:00
avpggq7IEemUbS_dyFLX8A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,adenylcyclase,naling cascades associated with , (Ac) down-regulation and decrea,TextQuoteSelector,TextPositionSelector,15572,15585,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:39:02.087855+00:00
aomn3q7NEemKJbMXpVwPig,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ADP receptor,irreversible block of the P2Y12 ,. Because of a distinct chemical,TextQuoteSelector,TextPositionSelector,28185,28197,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:14:48.812797+00:00
aMjNcq7CEemjDs9QuJsDdQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,GpIbα,rombinPAR-1; PAR-4 (secondary); ,Shape change; ADP and T×A2 secre,TextQuoteSelector,TextPositionSelector,10918,10923,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:56:01.162971+00:00
aBYVBK4aEemP7zdq6-rIuw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,acute myocardial infarction,o acute ischemic complications (,", ischemic stroke). In view of t",TextQuoteSelector,TextPositionSelector,8292,8319,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:53:24.619543+00:00
a-uizK9sEemMRlN7EBrrCg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,TAM membrane receptors,xy-terminal LG domains with the ,. Studies indicate an associatio,TextQuoteSelector,TextPositionSelector,51710,51732,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:13:01.123922+00:00
_9VmSK7DEembW3O5KyNTpQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,cyclooxygenase 1,erated from arachidonic acid by ," (COX-1) and T× synthase, furthe",TextQuoteSelector,TextPositionSelector,12454,12470,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:07:24.235676+00:00
ZyNriq7MEemxJIcWwGYRow,b53nbDmi,https://europepmc.org/articles/PMC3231843/,MerTK," of the TAM family (Tyro3, Axl, ",); through its vitamin K-depende,TextQuoteSelector,TextPositionSelector,27180,27185,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:07:33.547265+00:00
ZmEn0q7HEem2UZNs2Q20Sg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptors,"latelet activation, and Gαq and ", are involved in this process. T,TextQuoteSelector,TextPositionSelector,13742,13763,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:31:44.801464+00:00
ZOB8qK7JEemKFovEfA9g6Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PAD,ic peripheral arterial disease (,"), clopidogrel administered alon",TextQuoteSelector,TextPositionSelector,18155,18158,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:46:01.379225+00:00
Y_lK0K9qEemBbJdOCYGfmg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,myocardial infarction,",000 subjects with a history of ",", will evaluate the efficacy of ",TextQuoteSelector,TextPositionSelector,43733,43754,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:58:28.788912+00:00
YNsePK7KEemLbMeQBGdZvA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,cyclo-oxygenase,show that platelets with intact , activity can be detected into t,TextQuoteSelector,TextPositionSelector,21943,21958,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:53:04.017037+00:00
YBWdMK7IEemSOJMbJFkXCQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gai,hape change. P2Y12 is linked to ,-coupled signaling cascades asso,TextQuoteSelector,TextPositionSelector,15525,15528,"WT_DS,GP",no,[WT_DS][GP],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:38:43.723248+00:00
Xrc9qq7MEem-8Qvt3cBFVA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Axl,"RTKs) of the TAM family (Tyro3, ",", MerTK); through its vitamin K-",TextQuoteSelector,TextPositionSelector,27175,27178,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:07:19.387421+00:00
XQoJ4q7CEemDNPMei2h8IQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PAR-4,asodilating agentThrombinPAR-1; , (secondary); GpIbαShape change;,TextQuoteSelector,TextPositionSelector,10899,10904,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:55:41.595942+00:00
XA7_ZK7JEem8N1e9IGOR6A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CYP, activation by cytochrome P450 (,) liver isoenzymes. While the CA,TextQuoteSelector,TextPositionSelector,17943,17946,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:45:46.456844+00:00
X7_OHK7oEemLojdgnzNBjg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,intracranial hemorrhage,being associated with increased ,"), in elderly patients (aged ≥ 7",TextQuoteSelector,TextPositionSelector,34295,34318,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:27:47.114073+00:00
Wz5vUq7JEemLaReSxBu01g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,peripheral arterial disease," of AMI, stroke, or symptomatic "," (PAD), clopidogrel administered",TextQuoteSelector,TextPositionSelector,18126,18153,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:45:45.216768+00:00
Wix3tq4bEemcE6tiSDP0_w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombin,"2 (T×A2), serotonin (5-HT), and ",) recruit and activate additiona,TextQuoteSelector,TextPositionSelector,10018,10026,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:00:10.732101+00:00
VzS1vK7qEemNiwN8Gsd3YQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,liver dysfunction,ducers as well as a significant , may be of concern for its use (,TextQuoteSelector,TextPositionSelector,37457,37474,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:41:51.614569+00:00
V09R2K7MEemDVTeyIufuug,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Tyro3,nases (RTKs) of the TAM family (,", Axl, MerTK); through its vitam",TextQuoteSelector,TextPositionSelector,27168,27173,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:07:06.988351+00:00
UWq4NK7CEemfU_-wjrXrhA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PAR-1,g and vasodilating agentThrombin,; PAR-4 (secondary); GpIbαShape ,TextQuoteSelector,TextPositionSelector,10892,10897,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:55:22.132636+00:00
Tg7BZK7KEem8czuFO8BpYw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ABCB1,ulating clopidogrel absorption (,) have been associated with a hi,TextQuoteSelector,TextPositionSelector,21418,21423,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:52:32.467966+00:00
TfM2Bq9vEemT2d84MGYj0Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,renal dysfunction,"(e.g. elderly, low body-weight, ",) and avoided in patients with h,TextQuoteSelector,TextPositionSelector,42329,42346,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:33:39.275009+00:00
T0AFlrN8Eem-0NNCGdc3ug,b53nbDmi,https://europepmc.org/articles/PMC3231843/,G12,ets. P2Y1 is coupled to Gαq and ,. Gαq is linked to a signaling p,TextQuoteSelector,TextPositionSelector,15220,15223,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-31T10:16:49.614183+00:00
R7MyHK7MEemjOa8ylUKvoQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,TAM, tyrosine kinases (RTKs) of the ," family (Tyro3, Axl, MerTK); thr",TextQuoteSelector,TextPositionSelector,27156,27159,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:06:40.797456+00:00
QSy8Fq4cEemwrYusKxPp_w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ischemia," and oxygen supply, cause acute ", (5).Table IPlatelet activation:,TextQuoteSelector,TextPositionSelector,10445,10453,WT_DS,yes,[WT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:06:38.495481+00:00
QS2EOK7HEemneB9aP2NtDg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombin receptor, terminal domain (the so-called ,"), thrombin activates platelets ",TextQuoteSelector,TextPositionSelector,13222,13239,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:30:42.436346+00:00
PmnK-K7IEemaoA-sj4H-DQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,GP IIb," C (PKC) activation, leading to ",/IIIa activation and transient p,TextQuoteSelector,TextPositionSelector,15411,15417,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:37:47.227755+00:00
PBbpVK9rEemmLktBRSrR_A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CER,treatment of CAD patients. TRA* ," (71) is a prospective, randomiz",TextQuoteSelector,TextPositionSelector,49515,49518,WT_GP,no,[WT_GP],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:04:31.272946+00:00
OBIbRK7BEemyG0Of6v9wuw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gaq-coupled P2Y1,tReceptor(s)Effect(s)CommentsADP,; Gai-coupled P2Y12P2Y1: shape c,TextQuoteSelector,TextPositionSelector,10557,10573,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:47:29.887931+00:00
Nn-oxq7IEemUa8OlFenoaQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PKC,([Ca+2]i) and protein kinase C (,") activation, leading to GP IIb/",TextQuoteSelector,TextPositionSelector,15383,15386,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:37:34.027985+00:00
NhVUuK7qEemkdAOJYT01sQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,kidney failure,no dose adjustment is needed in ,". On the other hand, the concomi",TextQuoteSelector,TextPositionSelector,37347,37361,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:40:55.709372+00:00
NXtydq7CEemLRktQMznxCw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12,oupled P2Y12P2Y1: shape change; ,: aggregationP2Y12 amplifies agg,TextQuoteSelector,TextPositionSelector,10612,10617,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:54:35.193269+00:00
NWFs4K9tEemgOZcZH860Qw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,humans,ment of thrombotic disorders in ," (88). Individual bleeding risk,",TextQuoteSelector,TextPositionSelector,55040,55046,CRT_OG,no,CRT_OG,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:18:39.051544+00:00
MsVjbq7EEemLcN-KEU8oCQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,T× synthase,by cyclooxygenase 1 (COX-1) and ,", further amplifies platelet act",TextQuoteSelector,TextPositionSelector,12483,12494,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:08:49.512560+00:00
MS00Dq7KEem2Xgd5BuZZYQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CYP2C19,variety of polymorphisms in the , gene (most often the CYP2C19*2),TextQuoteSelector,TextPositionSelector,20741,20748,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:51:43.957695+00:00
Ls-TGq7JEemyNod7DoTGgA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,cytochrome P450, after a two-step activation by , (CYP) liver isoenzymes. While t,TextQuoteSelector,TextPositionSelector,17926,17941,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:44:30.666276+00:00
Lpb1ptCNEem3UguUerCh8g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,injury,latelet recruitment at sites of , (3). It may also play a pro-coa,TextQuoteSelector,TextPositionSelector,14269,14275,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:00:39.936730+00:00
Ljc3Pq7MEeml258e1rei1g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,RTKs,rane receptor tyrosine kinases (,") of the TAM family (Tyro3, Axl,",TextQuoteSelector,TextPositionSelector,27143,27147,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:05:58.030144+00:00
LYoOFK7IEemDSbt-W-DFdA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,protein kinase C,ium concentration ([Ca+2]i) and ," (PKC) activation, leading to GP",TextQuoteSelector,TextPositionSelector,15365,15381,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:37:18.905099+00:00
LJYpbK7qEembl6_q29Lh5Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CYP3A4,ve metabolite (AR-C124910XX) by , enzymes. Being both ticagrelor ,TextQuoteSelector,TextPositionSelector,37226,37232,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:40:40.109420+00:00
L1Xneq4bEem7IQ9CPU-4GA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,AMI,"), acute myocardial infarction (","), ischemic stroke) are the lead",TextQuoteSelector,TextPositionSelector,9658,9661,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:58:58.906212+00:00
Kq13Sq7HEemjJO_4zaB8DQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,hirudin,PAR-1 and PAR-4. By binding the ,-like extracellular amino termin,TextQuoteSelector,TextPositionSelector,13158,13165,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:30:04.621569+00:00
KLwwOK7DEemLTIdlIkxF7w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gai-coupled receptors,Y12 cross-reaction (via Gαq and ,)Serotonin5HT-2A receptorsShape ,TextQuoteSelector,TextPositionSelector,11073,11094,"WT_DS,GP",no,[WT_DS][GP],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:01:23.501582+00:00
JsExJq7CEemSw2eEp2_Nbw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,TPb,"5-HT, T×A2, and thrombinT×A2TPa;", (secondary)Shape change; platel,TextQuoteSelector,TextPositionSelector,10701,10704,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:54:10.559550+00:00
JL3oRK9qEemTFHMKx-z73Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,hyperuricemia,d with caution in patients with ,", bradyar-rhythmias without pace",TextQuoteSelector,TextPositionSelector,42194,42207,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:56:42.547505+00:00
JIcAfK4bEemXlN8Iq7Hlwg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ACS,rosis (acute coronary syndrome (,"), acute myocardial infarction (",TextQuoteSelector,TextPositionSelector,9623,9626,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:58:40.881845+00:00
IoSR1K7CEemKCAcPMWrZ6g,b53nbDmi,https://europepmc.org/articles/PMC3231843/,TPa," by 5-HT, T×A2, and thrombinT×A2",;TPb (secondary)Shape change; pl,TextQuoteSelector,TextPositionSelector,10697,10700,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:54:03.570169+00:00
Img2zq7MEemS5LevTAPyxQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,receptor tyrosine kinases, it interacts with the membrane , (RTKs) of the TAM family (Tyro3,TextQuoteSelector,TextPositionSelector,27116,27141,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:05:38.209367+00:00
IAvFLq7JEemyNdO90XHiUg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombotic thrombocytopenic purpura,"utropenia, aplastic anemia, and ", are the main limitations for a ,TextQuoteSelector,TextPositionSelector,17700,17735,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:44:05.887076+00:00
Hh2SXK9tEemgOAth0PCWrg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombotic disorders,newer strategy for treatment of , in humans (88). Individual blee,TextQuoteSelector,TextPositionSelector,55016,55036,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:17:59.859303+00:00
HTvxnK4bEem9aRs_7sPN5Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,mplications of atherosclerosis (," (ACS), acute myocardial infarct",TextQuoteSelector,TextPositionSelector,9598,9621,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:58:28.575557+00:00
Gnb4wK4cEempTVvd9DkiqA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombi, the formation of platelet-rich ," that, occluding the arterial lu",TextQuoteSelector,TextPositionSelector,10346,10353,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T14:05:33.448200+00:00
Gfmweq7DEem-nONIEOUvRg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Gαq,1 and P2Y12 cross-reaction (via , and Gai-coupled receptors)Serot,TextQuoteSelector,TextPositionSelector,11065,11068,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:00:58.627911+00:00
GO_CMK7KEemNvCNyHAAOYg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,hypercoagulable states,"iabetes mellitus, inflammation, ",", low fibrinolytic potential), h",TextQuoteSelector,TextPositionSelector,20026,20048,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:51:03.204057+00:00
GFv1BK7LEem8e4vimr8CCA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,hemorrhagic stroke,"come), and with a lower risk of ", (0.53% versus 2.01%; RR 0.26; 9,TextQuoteSelector,TextPositionSelector,25024,25042,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:58:11.820827+00:00
Fi1fUrN7EemK9J9f_ZEWuQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,(CYP) 2C19,notyping of the cytochrome P450 ," (*1,*2,*3,*4,*5,*6,*7,*8,*17) w",TextQuoteSelector,TextPositionSelector,38138,38148,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-31T10:08:04.134102+00:00
FGPGWK4bEemqAtMNH2gp3w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,atherosclerosis,tic (ischemic) complications of ," (acute coronary syndrome (ACS),",TextQuoteSelector,TextPositionSelector,9581,9596,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:58:13.746139+00:00
FBJUzK7JEemFVXt67Q_Zbg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,aplastic anemia,"on (16). Diarrhea, neutropenia, ",", and thrombotic thrombocytopeni",TextQuoteSelector,TextPositionSelector,17679,17694,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:43:45.678622+00:00
EoLfFq9sEemzQgvzmWAIRw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,growth factor,oagulant activity (74). Being a ,"-like molecule, as it interacts ",TextQuoteSelector,TextPositionSelector,51388,51401,WT_GP,no,[WT_GP],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:10:31.162787+00:00
DpalTK9qEemyv3uGROev4Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,hypotension,"ng ticagrelor. Dyspnea, nausea, ",", and asymptomatic ventricular p",TextQuoteSelector,TextPositionSelector,41969,41980,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:56:05.571557+00:00
De4wxq9tEemEBYNhxlGbwg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,acute coronary syndromes,nt has only been efficacious in ,". In addition, newer thienopyrid",TextQuoteSelector,TextPositionSelector,54345,54369,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:17:32.870474+00:00
Dd-qcK7MEemNa8eQhiCLUw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thromboembolism,i-Gas6 antibody lowers platelet , induced by the intravenous inje,TextQuoteSelector,TextPositionSelector,26887,26902,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:05:03.867920+00:00
DByovq7qEem7yTepUZCn_A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,phosphoinositide 3-kinase,"rylated VASP, and activation of ", are blocked. The net result is ,TextQuoteSelector,TextPositionSelector,36663,36688,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:39:45.543937+00:00
D0-GUK7CEemjDOMhuLdxqw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y1,-coupled P2Y1; Gai-coupled P2Y12,: shape change; P2Y12: aggregati,TextQuoteSelector,TextPositionSelector,10592,10596,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T09:53:31.198081+00:00
Cv4nWNCOEemtoRenN9lyag,b53nbDmi,https://europepmc.org/articles/PMC3231843/,platelet receptors,volves its interaction with two , belonging to the P2 purinergic ,TextQuoteSelector,TextPositionSelector,11390,11408,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:06:49.776034+00:00
CTOavK7IEemUao_4qmfi_A,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12,"rane domain receptors, P2Y1 and ",", to activate platelets. P2Y1 is",TextQuoteSelector,TextPositionSelector,15163,15168,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:36:18.077222+00:00
CJDsKq7KEemLa7_syIywiw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,diabetes mellitus,oncomitant clinical conditions (,", inflammation, hypercoagulable ",TextQuoteSelector,TextPositionSelector,19993,20010,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:50:35.980337+00:00
Bd9lYK4bEemwHHdBep8nDg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Thrombotic,platelet drugsGo to:Introduction, (ischemic) complications of ath,TextQuoteSelector,TextPositionSelector,9542,9552,WT_DS,yes,[WT_DS][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-24T13:57:49.371048+00:00
ApXXEK7IEem-IUfX4F18_Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y1,"transmembrane domain receptors, "," and P2Y12, to activate platelet",TextQuoteSelector,TextPositionSelector,15154,15158,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:36:06.586020+00:00
AdYg5K9vEem59_tVXVJHhQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,thrombospondin,nt; retention of fibrinogen and , on the platelet surfaceImplicat,TextQuoteSelector,TextPositionSelector,11184,11198,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:31:31.663979+00:00
AY4cmK9sEemx3y_Omf63CA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,protein S,as a 44% sequence homology with ,", it does not show any anticoagu",TextQuoteSelector,TextPositionSelector,51319,51328,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:10:02.558723+00:00
AJBMpq7JEem2XOdXCmJNxA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,neutropenia,"nt implantation (16). Diarrhea, ",", aplastic anemia, and thromboti",TextQuoteSelector,TextPositionSelector,17666,17677,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:43:13.000885+00:00
A5j29q7NEemLletk7hhCgg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CD 154, aggregationCD40 ligand (CD40L; ,)On activated platelets an exodo,TextQuoteSelector,TextPositionSelector,27620,27626,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:11:56.132718+00:00
A2UX7K7HEemyLreRPxPQQg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PARs,d protease-activated receptors (,) for thrombin: PAR-1 and PAR-4.,TextQuoteSelector,TextPositionSelector,13106,13110,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:28:58.769922+00:00
9duBCq7MEembeP_foBiPhA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CD40L,ed upon aggregationCD40 ligand (,; CD 154)On activated platelets ,TextQuoteSelector,TextPositionSelector,27613,27618,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:11:33.000270+00:00
9aoDsK7GEemxnSfIJSBR3Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,G-protein-coupled protease-activated receptors,telets express two cell surface , (PARs) for thrombin: PAR-1 and ,TextQuoteSelector,TextPositionSelector,13058,13104,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:28:35.592172+00:00
8EQVHK7DEemREXsoMzKPxQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,cardiovascular disease,r target for pharmacotherapy in ,.In spite of a significant antit,TextQuoteSelector,TextPositionSelector,12183,12205,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:06:58.119649+00:00
81h5cK7LEem-LUNqMw2fcA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Vitamin K-dependent protein, (growth arrest-specific gene 6),; a polyclonal anti-Gas6 antibod,TextQuoteSelector,TextPositionSelector,26810,26837,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:04:19.296603+00:00
7rtBcq7pEemJRz_xRULCcQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,t-PA,e tissue plasminogen activator (,") alone, or cangrelor (35, 140, ",TextQuoteSelector,TextPositionSelector,35628,35632,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:38:56.420858+00:00
7P4uDK7HEem4d48ptCkulQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,(COX)-l,let aggregation. Cyclooxygenase , catalyzes the production of T×A,TextQuoteSelector,TextPositionSelector,14939,14946,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:35:30.677122+00:00
6rddqK7MEemJI9tlzk_yMQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,CD40 ligand,ol and released upon aggregation, (CD40L; CD 154)On activated pla,TextQuoteSelector,TextPositionSelector,27600,27611,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:11:14.401340+00:00
6A7m3q9sEemzAZfisN8VJA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,ade-nylylcyclase, C activation and by inhibiting ,. The facilitating effects of PG,TextQuoteSelector,TextPositionSelector,53588,53604,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:16:29.421282+00:00
5gc6kq9pEem8Z6uaX4SooA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,intracranial bleedings," 3.8%; P=0.03), including fatal ",", were detected in subjects on t",TextQuoteSelector,TextPositionSelector,41326,41348,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T05:54:57.403358+00:00
5CJrqq7GEemLXnueGDwPkQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Human, major platelet activators (8). , platelets express two cell surf,TextQuoteSelector,TextPositionSelector,13017,13022,CRT_OG,yes,[CRT_OG][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:28:06.359920+00:00
4_1iRq7HEem0Jf-9OzodOA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,Cyclooxygenase,sustained platelet aggregation. , (COX)-l catalyzes the productio,TextQuoteSelector,TextPositionSelector,14924,14938,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:35:15.398234+00:00
4AU1Pq7LEemxItfv-MUrjg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,growth arrest-specific gene 6,d aggregationOrally activeGas6 (,)Vitamin K-dependent protein; a ,TextQuoteSelector,TextPositionSelector,26780,26809,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:03:46.901724+00:00
3zRbZq7MEemFXzcqfTD1Tw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,MMP-2,"y potentiating PI3K activation, ", amplifies platelet aggregation ,TextQuoteSelector,TextPositionSelector,27353,27358,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T11:10:54.907864+00:00
3MN56q7KEemkk6vfs8naeg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PDE3,eting phosphodiesterase type 3 (,") and, then, determining intrace",TextQuoteSelector,TextPositionSelector,24471,24475,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:56:31.925827+00:00
1V-A1q7KEemlBFOnaRctEw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,phosphodiesterase type 3,"lostazol, selectively targeting "," (PDE3) and, then, determining i",TextQuoteSelector,TextPositionSelector,24445,24469,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:56:19.567776+00:00
1MtFCq9rEembgbvgktqYjQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,limb ischemia, previous revascularization for ,. Participants are randomized to,TextQuoteSelector,TextPositionSelector,50561,50574,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:08:47.485799+00:00
1IT5Iq7DEemIt4PNZJdg2Q,b53nbDmi,https://europepmc.org/articles/PMC3231843/,P2Y12 receptor, whereas the signaling from the , facilitates sustained irreversi,TextQuoteSelector,TextPositionSelector,11751,11765,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:06:11.599703+00:00
0tb4oK7IEemJaStTuKguOQ,b53nbDmi,https://europepmc.org/articles/PMC3231843/,purinergic receptor,action of ADP with its platelet , and to determine the inhibition,TextQuoteSelector,TextPositionSelector,17214,17233,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:41:56.269877+00:00
0cmGzK7HEemUaSN7Ou6eYw,b53nbDmi,https://europepmc.org/articles/PMC3231843/,PLC," shape change, phospholipase C (",") activation, thromboxane A2 (T×",TextQuoteSelector,TextPositionSelector,14769,14772,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T10:34:45.006119+00:00
0a6-jK9sEem4QEcyONkV0w,b53nbDmi,https://europepmc.org/articles/PMC3231843/,integrin αIIbβ3,CD40L) is released and binds to ," on activated platelets, thus pr",TextQuoteSelector,TextPositionSelector,52955,52970,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:15:51.869702+00:00
0ARWiK7pEemnsdehmD72rg,b53nbDmi,https://europepmc.org/articles/PMC3231843/,tissue plasminogen activator,"280 μg/kg/min) alone, full-dose "," (t-PA) alone, or cangrelor (35,",TextQuoteSelector,TextPositionSelector,35598,35626,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-25T14:38:04.961356+00:00
-QSweK9rEemzQSdEQbgpiA,b53nbDmi,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent proteins,"e 6), a member of the family of ",", is stored in platelet α granul",TextQuoteSelector,TextPositionSelector,51173,51201,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-26T06:09:48.343846+00:00
